In contrast, +SA mammary tumors from mice treated with the δ-tocotrienol oxazine derivative, compound 44, displayed a relatively large and significant decrease in HIF-1α, phospho-Akt, phospho-ERK1/2, phospho-mTOR, phospho-p70S6K, and phospho-eIF-4E1 levels and a corresponding increase in the levels of phospho-4E-BP1 (Figure 8(b)). The gene discussed is MAPK3; the disease is breast cancer.